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Both tumor-speciﬁc CD4+ and CD8+ T cells have been identiﬁed, and the latter is known as a major eﬀector of adaptive antitumor
immune responses. Optimal antitumor immune responses are considered to require the concomitant activation of both CD8+ and
CD4+ T cells and the additional selective activation of CD4+ T cells with helper, but not regulatory function. As optimal antitumor
immune responses are generated by the concomitant activation of both T cell types, it is necessary for vaccine methods involving
cytotoxic T-lymphocytes (CTLs) generation to possess a mechanism whereby antigen presenting cells can present administrated
exogenous antigens on not only Major histocompatibility complex (MHC) class II, but also MHC class I molecules.
1.Introduction
We have previously reported the development of a new drug
delivery system (DDS) based on the carbohydrate recog-
nition properties of phagocytic cells to control metastatic
cancer in extranodal lymphoid tissue of the abdominal
cavity [1]. Further, we demonstrated that our DDS could be
used for the induction of CTLs through the presentation of
exogenous antigens on MHC class I molecules of phagocytic
cells [2].
Inaccordancewithﬁndings frommanyattempts,includ-
ing ours, to generate antigen-speciﬁc CTLs, this paper
provides an overview of current trials of liposome-based
vaccines. Furthermore, we discuss the feasibility concerning
our vaccination technique by summarizing accumulated
knowledge regarding receptor candidates.
2. Overview
In order to reject invading pathogens and cancer cells,
expansion of T cells is known to be activated by small
peptides on Major histocompatibility complex (MHC) class
I or MHC class II molecules on the cell surface of antigen-
presenting cells (APCs) such as dendritic cells (DCs) and
macrophages.Wewillmainlyintroducerecentprogressionof
vaccine methods to generate CD8+ cytotoxic T lymphocytes
(CTLs) in this paper, while ﬁrst mentioning the indispens-
able roles of CD4+ helper T cells that support the expansion
and persistence of CTLs [3–5]. Indeed, optimal antitumor
immune responses are generated by the concomitant activa-
tion of both CD8+ and CD4+ T cells because of the selective
activation of CD4+ T cells with helper, but not regulatory
functions [6]. Generally, exogenous antigens presented by
MHC class II molecules are intended for CD4+ T cells,
whereas internal antigens from the cell itself, components
of virus infected cells, and cancer antigens are presented on
MHCclassImoleculesforactivationandexpansionofCD8+
Tcells.Consequently,itisnecessaryforvaccinedevelopment
methods involving CTL generation to possess a mechanism
whereby administrated exogenous antigens can be presented
not only on MHC class II, but also class I molecules of APCs
[6–8].
For vaccine development methods whereby exogenous
antigens are exhibited both on MHC class I and class II
moleculestoinduceantigen-speciﬁcCD8+ andCD4+ Tcells,2 Journal of Biomedicine and Biotechnology
our novel drug delivery system (DDS) using oligomannose-
coated liposomes (OMLs) [1] that target phagocytic cells
can be tailored for this purpose [2]. Indeed, a novel OML-
based vaccine could reject transplanted tumor cells, prevent
progression of encephalitis and vertical transmission, and
reduce oﬀspring mortality of Neospora caninum as shown in
a feasibility study for its clinical use [2, 9–11].
OML-based vaccines produce strong adjuvanticity for
CTLs. As liposomes coated by oligomannose are exclusively
taken up by F4/80+ intraperitoneal mononuclear cells and
gatheredatextranodallymphoidtissues,theso-called“milky
spots in abdominal cavity” [1], the underlining mechanisms
of OML-based vaccine appear to be accompanied by an
immune surveillance system for detecting pathogens invad-
ing the abdominal cavity in either a mannose dependant
or mannose independent manner. Important roles for
macrophagesandcomplementsystemsarewellknowninthe
clearance of foreign materials, invading bacteria, and tumor
cells from the abdominal cavity. Moreover, it is the milky
spots that are the exact locus of this clearance process [12–
15].Takentogether,alineofclearanceprocessforOMLsmay
associate with strong adjuvanticity to induce CTLs.
Some diseases such as hepatitis C virus infection and
malignancies still remain to have vaccine methods devel-
oped for them using disease-speciﬁc CTLs by elucidating
their basic roles [5, 16, 17]. Many attempts to generate
antigen-speciﬁc CTLs have been conducted, based on new
experimental evidence. In accordance with these eﬀorts, this
paper will provide an overview of current trials concerning
liposome-based vaccine delivery, and we discuss the feasibil-
ity of an OML-based vaccine based on recently accumulated
knowledge of the carbohydrate recognition system as a target
for OML-based vaccine delivery systems.
2.1. Liposome-Based Vaccine Delivery to Generate CTLs.
Based on results from materials investigated for immu-
nization, many types of liposomes have been tested for
use in attempts to increase the eﬀect of CTL generation
against delivered vaccine antigens. New materials used in
liposome preparation have been investigated to see whether
they could eﬀectively generate CTLs while monitoring the
following three eﬀects [18–20]: (1) an increase in the fusion
eﬃciency between the cell membrane and liposomes, (2)
the stabilization of liposomes in blood circulation, and (3)
eﬃcient delivery of vaccine antigens to APCs.
The approach tried ﬁrst was to increase the fusion eﬃ-
ciency between the cell membrane and liposomes, because
external antigens spilling from endosomes into the cytosol
is considered to be the most important step for entry
into the class I processing pathway for CTL generation
[18, 21, 22]. To this purpose, use of peptide sequences
referred to as antennapedia homeodomain [23, 24], and
the hemolytic protein of Listeria monocytogenes, listeriolysin
O[ 25], succeeded in enhancing the introduction of CTL
epitopes into the class I processing pathway, resulting in
the increased generation of CTLs. Furthermore, fusogenic
liposomes prepared by fusing simple liposomes with Sendai
virus particles can deliver encased antigens into the cytosol
to generate CTLs [26].
Retaining liposomes in blood circulation is another way
to increase the eﬃciency of CTL generation. Increasing
retention time has been achieved by reducing surface-
macromolecule interaction, which provides less opportunity
for liposomes uptake by phagocytic cells and hepatocytes
[27, 28]. The approach is highly eﬀective for induction of
CTLs against antigens encased in liposomes [29, 30]. To
thispurpose, polyethyleneglycol(PEG)-modiﬁed lipids have
become universally used in the preparation of liposomes
(PEG-liposome) [29–31], which can more greatly enhance
the generation of a CD8+ T cell response than when given
in soluble form or in conventional or positively charged
liposomes [32]. Moreover, new lipids isolated from Archaea
have also been used in the preparation of liposomes because
of their stabilizing eﬀect on liposomes in a manner similar
to that for PEG-modiﬁed lipids. Archaea liposomes showed
higher stability against extreme pH, oxidation, elevated tem-
peratures, and action of lipases than conventional liposomes
[33–35].
While higher stabilization in blood circulation increases
CTL generation as discussed above, enhanced uptake by
phagocytic cells has been indicated to elicit strong adju-
vanticity to induce antigen-speciﬁc CTL responses [19].
The relevant examples of speciﬁc delivery of liposomes to
phagocytic cells are cationic liposomes and OMLs. Positive
charge on a liposome surface enhances uptake by APCs
more than neutral membranes, and more robust immune
responses for CTL generation and antibody production were
seen in mice immunized using positively charged liposomes
than with neutral liposomes [23, 28, 36–38]. To add
positive charge to the surface of liposomes in earlier stud-
ies, cationic cholesterol derivatives such as 3β[N-(N
 ,N
 -
dimethylaminoethane)-carbamyl] cholesterol hydrochloride
were frequently used.
Coating with ligands for pattern recognition receptors
such as a mannose receptor (MR) on APCs is expected
to have the analogous eﬀect of adding positive charge to
the liposome surface using cationic cholesterol derivatives,
because ligand binding triggers endocytosis of liposomes by
APCs such as DCs and macrophages [39, 40]. Related to
this concept, Chikh et al. have indicated a line of phagocytic
receptors for a variety of ligands, FCγ RI [41, 42], mannose
[39, 40], αMβ2 integrin (CD11b CD18) [43, 44], CD36, and
αvβ5 integrin [45], for forced uptake by APCs [19].
2.2. Carbohydrate Coatings on Liposomes to Deliver Vaccine
Antigen to APCs. To induce robust immune responses using
carbohydrates recognition by phagocytic cells, either man-
nose residues coupling on antigens or coating on an antigen
encased liposomes appears to show promise. Using these
methods, antigens were able to eﬃciently deliver phagocytic
cellssuchasAPCs,duetotheuptakebymannoserecognition
r e c e p t o r ss u c ha sm a c r o p h a g em a n n o s er e c e p t o r( M M R ,
CD206) and DC-speciﬁc intercellular adhesion molecule
(ICAM)-3-grabbing nonintegrin (DC-SIGN) preferentially
expressed on them, resulting in eﬀective induction of CTLs
[1, 46–50]. It may be associated with a nature of mannose
residues, which signiﬁcantly enhances immunogenicity of
antigens and strongly promotes DC maturation throughJournal of Biomedicine and Biotechnology 3
TLR4 function [51]. Concerning carbohydrate coupling on
antigen,notonlythehigh-mannoseoligosaccharide[47]and
O-linked short mannose (2-3 mannoses) from P. pastoris
[48–50], but also fucosylated oligosaccharides such as Lewis
Xo rL e w i sB[ 50], could be used to speciﬁcally deliver to
dendritic cell by the other preferential binding speciﬁcity
of DC-SIGN. Indeed, either mannosylated or fucosylated
antigens could enhance CTLs responses depending on
antigen presentation via class I molecules. [47, 49, 50].
Concerning mannose residues coating on liposome
surfaces, we used mannotriose-dipalmitoylphosphatidyleth-
anolamine (Man3-DPPE) [52] in the preparation of lipo-
someswithdipalmitoyl phosphatidylcholine andcholesterol,
at a molar ratio of 1:10:10 [52, 53]. Man3-DPPE, a
neoglycolipid that is composed of Man3 and DPPE, is
synthesized by reductive amination between an aldehyde
group of oligosaccharides and the amino group of DPPE
[52]. Because of the hydrophobic lipid moiety of the
neoglycolipid, Man3-DPPE can easily be incorporated into
the lipid bilayer of liposomes. The liposomes contain Man3-
DPPE, and we have named them OMLs.
As mentioned in our previous studies, OMLs injected
into the abdominal cavity are taken up by CD11b+ phago-
cytic cells that deliver material to milky spots [1, 46]. Indeed,
when 5-ﬂuorouracil (5-FU) was encapsulated in the OMLs,
morethan60%oftheadministered 5-FUaccumulatedinthe
omentum where milky spots gathered [1]. In other words,
the OML-based DDS targets CD11b+ phagocytic cells that
act as cellular vehicles for material delivery. Recent use of
hematopoietic or mesenchymal stem cells as cellular vehicles
has led to signiﬁcant progress in gene delivery techniques,
whileBurkehasindicatedtheadvantagesofusingphagocytic
cells as natural cellular vehicles [54]. Phagocytic cells such as
macrophages in the abdominal cavity take up large amounts
of particles and accumulate them at not only lymphoid
tissue, but also various pathological sites such as cancer
lesions, wounds, atherosclerotic plaques, and arthritic joints
[54]. Consequently, for delivery of materials, OMLs are a
valuable tool for exploiting the nature of phagocytic cells.
We recently demonstrated the usefulness of OMLs as
carriers for the delivery of vaccine antigen to generate and
expand CTLs by employing ovalbumin (OVA) as a model
cancer antigen [2]. Indeed, APC came to express OVA-
derived peptides obtained by OML-based delivery in the
context of both MHC class I and II molecules, which were
evaluated by the detection of interferon gamma (IFNγ)
production in the coculture with OML-delivered APCs and
either CD8+ or CD4+ T cells from the spleens of T cell recep-
tor transgenic mice OT-I (speciﬁc for H-2Kb/OVA257–264)
[55, 56] or OT-II (H-2Ab/OVA323–339)[ 57], respectively [2].
Moreover, only the spleen cells from mice immunized with
OML-OVA, but not bare liposomes without coating-encased
OVA, showed cytotoxicity against E.G7-OVA, and only the
mice preimmunized with subcutaneous challenge by OML-
OVA rejected E.G7-OVA, but not EL4. These results together
indicate that the OMLs can be used as an eﬀective antigen
delivery system for immunotherapy activating both CTL
and Th subsets. OMLs are very useful not only for the
promotion of nonglycosylated protein uptake by APCs, but
also for the enhancement of antigen processing of encased
antigens. This advantage of OML-mediated immunization
will hopefully facilitate the simultaneous activation of tumor
antigen-speciﬁc CD4+ and CD8+ T cells [2], and have the
potential for use in cancer immune therapy [9].
It is well known that carbohydrates binding protein on
APCs and complement lectin pathways recognize conserved
motifs of glycans on pathogens. Carbohydrates binding
proteins on phagocytic cells participate in the capture
of materials to internalize, while the complement lectin
pathway actively generates peptide fragments from C3,
facilitating opsonophagocytosis by phagocytic cells through
the complement receptors (CRs). Inhibition of complement
component C3 and complement receptor type 3 (CR3,
CD11b/CD18) could block the uptake process of OMLs by
phagocytic cells [58, 59]. These observations support the
hypothesisthatcarbohydratesbindingreceptorspromotethe
uptake of liposomes in accordance with the activated lectin
pathway, acting as an essential step in robust CTL responses
against antigens encased in liposomes [59–61].
3.PossibleTarget Receptorson APCsUsing
Liposomes withCarbohydrateCoatings
In this section, we focus on receptor candidates on
APCs for uptake of liposomes with carbohydrate coatings.
B a s e do nr e c e n ta d v a n c e m e n t si nt e c h n o l o g i e st oi n v e s t i -
gate structure–function relationships of glycans, knowledge
about the properties of carbohydrate-binding proteins has
dramaticallyincreased,andoﬀerstheirpossibleuseastargets
for the delivery of vaccine antigens. Here, we introduce DC-
SIGN (CD209), MMR (CD206), and CRs to illustrate the
possible mechanism for OML delivery to induce CTLs.
DC-SIGN (CD209) is a type II membrane protein, which
is now established as a mannose-binding protein [62], and
which appears to be a major receptor for OMLs [63]. It
exhibitshigheraviditytomannosethroughmultimerforma-
tion,whilethereisnotaone-to-onecorrespondencebetween
the mannose and carbohydrate recognition domains (CRD)
of DC-SIGN because of the binding speciﬁcity for N-
acetylglucosamine (GlcNAc) and fructose (fuc) [62]. DC-
SIGN was initially reported as having speciﬁc binding for
HIV gp120 [64], and further, ICAM-2 and ICAM-3 on T
cells were identiﬁed as ligands [65]. Because the interaction
between DC-SIGN and ICAM-3 is inhibited by added free
mannose, mannose residues of ICAM-3 act as ligands for
CRD of DC-SIGN [65]. Though the ligand binding has been
considered to enhance T cell activation by MHC class II
(and possibly MHC class I) molecules in a restricted manner
[66, 67], the exact role of how DC-SIGN associates to induce
and activate CTLs remains to be elucidated.
The initial immunological role of MMR/CD206 has been
considered to be for the surveillance of invading pathogens
such as Candida albicans and Pneumocystis carinii [68,
69]. MMR has eight CRD/C-type lectin-like carbohydrate
recognition domains, one ﬁbronectin type II repeat domain
(Fn-II D), ﬁve CRDs (CRD4–8), which bind with mannose,
but also fuc and GlcNAc [70, 71]. Targeted delivery using a
speciﬁc antibody to MMR increases the uptake of delivered4 Journal of Biomedicine and Biotechnology
Table 1: Lectin-like receptors, complement receptors (CR), and ligands.
Receptors Ligands
DC-SIGN (CD209) Fucose, mannose, N-acetylglucosamine
DEC-205(CD205) Unknown
Mannose receptor (CD206) Fucose, mannose, N-acetylglucosamine
CR1 (CD35) C3b, iC3b
CR2 (CD21) C3d
CR3 (CD11b/CD18, Mac-1) iC3b
CR4 (CD11 c/CD18) iC3b
CR5 (CRlg, VSIG4) iC3b
antigens by phagocytic cells, resulting in the concomitant
activation of both CD8+ and CD4+ T cells through antigen
presentation on MHC class I and class II molecules [39, 72].
This observation suggests a possible role of MMR in the
induction of CTLs when OML is used for immunization.
Though DEC-205/CD205 has 10 CRDs and is highly
homologous with MMR, its avidity to any glycans has not
been detected. It may be caused by the limited number
of glycan structures to perform binding analysis [73–75].
DEC-205 expresses exclusively on mature DCs, but for
macrophage and immature DCs, targeting DEC-205 to
deliver liposome-containing vaccine antigen has the poten-
tial to improve the eﬃciency of CTL generation because of
possible adjuvanticity [76].
To date, ﬁve members of CRs (CR1-5) have been
identiﬁed,andallofwhichareassociatedwithopsonophago-
cytosis through the activation of the complement system
[77]. Expression of all CRs has been exclusively detected
on monocyte/macrophage lineage cells, while the distinct
presence of CR1 and CR2 on erythrocytes and B cells is
known [78].Table 1 showsthediﬀerential binding speciﬁcity
of each CR for C3 fragments [79–81].
CRs appear generally to have other functions besides
facilitatingopsonophagocytosis,knownastheirclassicalrole.
CRIg/VSIG4 is a recently identiﬁed ﬁfth member (CR5) of
the CR family, the long form of which is identical to Z39Ig
reported in earlier studies [78, 81]. CR5, CRIg/VSIG4/Z39Ig,
on monocytic cells can bind C3b and iC3b to internalize
opsonized materials in the same way as other CRs, while it
appears to play other roles, such as B7 family molecules, to
suppress the activation and proliferation of CTLs [82, 83].
In addition, CR2/CD21 on B cells was demonstrated to
transduce positive signals for antibody production upon
complex formation with CD19 and CD81 [84]. Taking into
account that CRs have another function besides internaliza-
tion, CR3 (CD11b/CD18, Mac-1) [85] and CR4 (CD11b)
may play some role in generating CTLs upon taking up OML
[84, 85].
4. Possible InfectiousDiseaseTargets for
a Vaccine Strategy Using OMLs
In order to prevent manifestation of some diseases whose
main eﬀectors are CTLs, administration of recombinant
antigen as a vaccine requires particular adjuvants to induce
CTLs suﬃciently to reject causative pathogens. To date, live
vaccines are exclusively applied for universal prophylaxis of
domesticanimals,becausetheyappeartohavehighereﬃcacy
for illness given infection than either recombinant or inacti-
vated vaccine containing adjuvant because of the advantage
of induction eﬃciency of CTLs. Because vaccination with
OMLs is expected to induce concomitant activation of both
CTLs and Th1 cells, it has the potential to alter general
approaches for infection control in domestic animals from
live vaccines to recombinant antigen.
Based on increasing knowledge regarding OML-based
vaccines, we have attempted to use them for control of some
infectious diseases. Promising results using OMLs could
be obtained for infection by N. caninum [10]a n dLeish-
mania major [53] using animal models. By administration
of Neospora antigen NcGRA7 encased in OMLs to mice,
NcGRA7-speciﬁc Th1 cells were generated, preventing the
transitionoftheinfectiontothebrainandtransplacentalver-
tical transmission [10]. Moreover, administration of apical
membrane antigen 1 of Neospora using OMLs succeeded to
reduce oﬀspring mortality [11]. Whether the induced CTLs
eliminatedN.caninumininfectedmice,itremainedtodeter-
mine increased numbers of the infection-speciﬁc CTLs by
ELISpot assay, and estimate disease activity using genetically
engineeredprotozoansexpressingOVAassurrogateantigens.
For the L. major infection, as earlier models with genetically
engineered protozoans showed important roles of CTLs in
the elimination of L. major [86] similar to the intracellular
protozoan parasite Toxoplasma gondii [87], both antigen
speciﬁc CTLs and Th1 cells induced by OML vaccination
wouldshoweﬃcacyinpreventingdevelopmentoftheillness.
WeconsiderthatCTLgenerationbyOML-basedvaccines
can also be applied to Theileriosis. Theileriosis is a serious
infection in cattle caused by tick-borne parasites, and
is classiﬁed as a lymphoproliferative or hemoproliferative
disease, depending on the principal pathogenic feature. T.
parva and T. annulata are agents of lymphoproliferative
Theileriosis [88, 89], and CTLs against T. annulata and
T. parva are known to prevent disease progression [90,
91]. To date, live vaccine is known to be eﬃcacious as
a prophylactic agent. Administration of either T. annulata
attenuated by long time in vitro culture or the infection-
and-treatment method for T. parva [92, 93] are known as
eﬀective vaccination methods preventing the development
of the lymphoproliferative disease. These results suggest thatJournal of Biomedicine and Biotechnology 5
it is possible to use OML vaccines to prevent the onset of
lymphoproliferative Theileriosis.
5. Conclusion
In accordance with the ﬁndings from many attempts to gen-
erate antigen-speciﬁc CTLs, this paper presents an overview
of current trials concerning liposome-based vaccine delivery.
We discuss the feasibility of using OML-based vaccine based
on recently accumulated knowledge regarding carbohydrate
recognition systems as targets for OML-based vaccine deliv-
erysystems.InordertopracticallyuseOML-basedvaccineto
introduce CTLs for prophylaxis of some infectious diseases,
general use of ELISpot assays may be needed to monitor the
eﬃcacy of CTL generation. Taking into account the recent
trend of surveying for latent infection of Mycobacterium
tuberculosis [94] using this method, universal use of OML-
based vaccine to induce CTLs is not limited by this issue.
Further studies characterizing the type of immune response
induced by OML-based vaccine delivery in cattle are planned
and should provide additional insights for the optimal
development of OML-based vaccine to generate CTLs.
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